ST
PTLA

Spot Trading’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Spot Trading’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-5,430
Closed -$134K – 3995
2016
Q1 		$111K Buy
+5,430
New +$172K ﹤0.01% 2519

Other funds holding PTLA

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Spot Trading's PTLA Position: Q2 2016 in Review

Spot Trading sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2016, closing a stake of 5,430 shares — an estimated $134K sold.

Spot Trading first reported a position in PTLA in Q1 2016 and held it in 1 quarter. The position peaked at $111K in Q1 2016. 159 funds tracked by Wall St. Rank hold PTLA as of Q2 2016.

  • Spot Trading reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
  • Spot Trading sold 5,430 Portola Pharmaceuticals, Inc. shares in Q2 2016, an estimated $134K.
  • Spot Trading first reported a position in Portola Pharmaceuticals, Inc. in Q1 2016 and held it in 1 quarter.
  • Spot Trading's Portola Pharmaceuticals, Inc. position peaked at $111K in Q1 2016.
  • 159 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2016.

Based on Spot Trading's 13F filing for Q2 2016, filed 2 Aug 2016.